In: Ecotoxicology and environmental safety: EES ; official journal of the International Society of Ecotoxicology and Environmental safety, Band 209, S. 111848
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) ; European Union Grant LIFECYCLE ; Norwegian Research Council BIOTEK2021 program ; project SALMOSTERILE ; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) ; Processo FAPESP: 12/00423-6 ; Processo FAPESP: 14/07620-7 ; European Union Grant LIFECYCLE: FP7-222719 ; project SALMOSTERILE: 221648 ; CNPq: 201488/2014-0 ; Fsh-mediated regulation of zebrafish spermatogenesis includes modulating the expression of testicular growth factors. Here, we study if and how two Sertoli cell-derived Fsh-responsive growth factors, anti-Mullerian hormone (Amh; inhibiting steroidogenesis and germ cell differentiation) and insulin-like growth factor 3 (Igf3; stimulating germ cell differentiation), cooperate in regulating spermatogonial development. In dose response and time course experiments with primary testis tissue cultures, Fsh up regulated igf3 transcript levels and down-regulated amh transcript levels; igf3 transcript levels were more rapidly up-regulated and responded to lower Fsh concentrations than were required to decrease amh mRNA levels. Quantification of immunoreactive Amh and Igf3 on testis sections showed that Fsh increased slightly Igf3 staining but decreased clearly Amh staining. Studying the direct interaction of the two growth factors showed that Amh compromised Igf3-stimulated proliferation of type A (both undifferentiated [A(und)] and differentiating [A(diff)]) spermatogonia. Also the proliferation of those Sertoli cells associated with Aund spermatogonia was reduced by Amh. To gain more insight into how Amh inhibits germ cell development, we examined Amh-induced changes in testicular gene expression by RNA sequencing. The majority (69%) of the differentially expressed genes was down-regulated by Amh, including several stimulators of spermatogenesis, such as igf3 and steroidogenesis-related genes. At the same time, Amh increased the expression of inhibitory signals, such as inha and id3, or facilitated prostaglandin E-2 (PGE(2)) signaling. Evaluating one of the potentially inhibitory signals, we indeed found in tissue culture experiments that PGE(2) promoted the accumulation of Aund at the expense of Ada and B spermatogonia. Our data suggest that an important aspect of Fsh bioactivity in stimulating spermatogenesis is implemented by restricting the different inhibitory effects of Amh and by counterbalancing them with stimulatory signals, such as Igf3. (C) 2017 Elsevier B.V. All rights reserved.
Understanding the spatiotemporal patterns of legacy organochlorines (OCs) is often difficult because monitoring practices differ among studies, fragmented study periods, and unaccounted confounding by ecological variables. We therefore reconstructed long-term (1939–2015) and large-scale (West Greenland, Norway, and central Sweden) trends of major legacy OCs using white-tailed eagle ( Haliaeetus albicilla ) body feathers, to understand the exposure dynamics in regions with different contamination sources and concentrations, as well as the effectiveness of legislations. We included dietary proxies ( δ 13 C and δ 15 N) in temporal trend models to control for potential dietary plasticity. Consistent with the hypothesised high local pollution sources, levels of polychlorinated biphenyls (PCBs), dichlorodiphenyltrichloroethanes (DDTs) and hexachlorocyclohexanes (HCHs) in the Swedish subpopulation exceeded those in the other subpopulations. In contrast, chlordanes (CHLs) and hexachlorobenzene (HCB) showed higher concentrations in Greenland, suggesting the importance of long-range transport. The models showed significantly decreasing trends for all OCs in Sweden in 1968–2011 except for CHLs, which only decreased since the 1980s. Nevertheless, median concentrations of DDTs and PCBs remained elevated in the Swedish subpopulation throughout the 1970s, suggesting that the decreases only commenced after the implementation of regulations during the 1970s. We observed significant trends of increasing concentrations of PCBs, CHLs and HCB in Norway from the 1930s to the 1970s/1980s and decreasing concentrations thereafter. All OC concentrations, except those of PCBs were generally significantly decreasing in the Greenland subpopulation in 1985-2013. All three subpopulations showed generally increasing proportions of the more persistent compounds (CB 153, p.p ′-DDE and β -HCH) and decreasing proportions of the less persistent ones (CB 52, p.p ′-DDT, α - and γ -HCH). Declining trends of OC concentrations may imply the decreasing influence of legacy OCs in these subpopulations. Finally, our results demonstrate the usefulness of archived museum feathers in retrospective monitoring of spatiotemporal trends of legacy OCs using birds of prey as sentinels.
WOS: 000482433800011 ; PubMed ID: 30467691 ; Purpose The aim of the current study was to further investigate the concept of previously reported high occurrence of comorbidities in obstructive sleep patients (OSA) with insomnia-like symptoms. We hypothesized that this finding at least partly is mediated by nocturnal hypoxia. Moreover, we speculated that the spectrum of the clinical OSA phenotypes differs between European geographical regions. Methods Cohort of the European Sleep Apnea Database (n = 17,325; 29.9% females) was divided into five subcohorts according to geographical region (North, East, South, West, Central) and further into four clinical presentation phenotypes based on daytime symptoms (EDS) and characteristics suggestive of insomnia. Results The insomnia phenotype (alone or together with EDS) dominated in all European regions. Isolated insomnia, however, was less common in the West. Insomnia phenotype was associated with the highest proportion of cardiovascular comorbidity (51.7% in the insomnia vs. 43.9% in the EDS type). Measures of nocturnal hypoxemia were independently associated with cardiovascular comorbidity in phenotypes with insomnia-like symptoms. The burden of comorbidities was high across all geographical regions and clinical phenotypes. Regional differences were clinically relevant for age (48 vs. 54 years), BMI (29 vs. 34 kg/m(2)), and ODI (15 vs. 32/h). Conclusion High prevalence of particularly cardiovascular comorbidity among patients with insomnia-like symptoms was linked to nocturnal hypoxemia. Considerable differences in clinical presentation were found among OSA patients across Europe. Our data underline that physicians should ask their patients with suspected OSA also for insomnia symptoms. It remains to be explored if a reduction of nocturnal hypoxemia predicts the improvement of insomnia symptoms. ; European Union COST action B26; European Respiratory Society (ERS); ResMed Inc.; Philips Respironics Inc. ; The ESADA network has received support from the European Union COST action B26. The European Respiratory Society (ERS) supports the ESADA for the second period as a Clinical Research Collaboration (CRC) (2015-2017 and 2018-2020). Unrestricted seeding grants from ResMed Inc. and Philips Respironics Inc. for establishment of the organization and the database are gratefully acknowledged.
The authors regret that they have to correct the acknowledgement of the above mentioned publication as follows: This article/publication is based upon work from COST Action BM1203 (EU-ROS), supported by COST (European Cooperation in Science and Technology) which is funded by the Horizon 2020 Framework Programme of the European Union. COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. For further information see www.cost.eu. The authors would like to apologise for any inconvenience caused. ; This article/publication is based upon work from COST Action BM1203 (EU-ROS), supported by COST (European Cooperation in Science and Technology) which is funded by the Horizon 2020 Framework Programme of the European Union. COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks.